Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants

Trial Profile

Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NOAC
  • Sponsors GWT-TUD GmbH
  • Most Recent Events

    • 12 Dec 2017 Results (Data cut off June 30, 2017; n=23) assessing effectiveness and safety of rivaroxaban in splanchnic vein thrombosis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 19 Jan 2017 Protocol was amended and treatment arms were changed to 4 and planned patient number changed from 2000 to 3500.
    • 19 Jan 2017 Planned number of patients changed from 2000 to 3500.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top